Form D · Biotechnology
Qu Biologics Inc.
Burnaby, A1 · CIK 0001742632
Offering snapshot reported Jun 5, 2018 · SEC filing
- Reported sold
- $48.8K Offering amount: $77.6K
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 24, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 5, 2018 | Initial | $48,811 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired, Other
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-313935
Aggregate offering includes amount that may be received by Issuer upon exercise of warrants; each warrant may be exercised for 1 common share at CDN$6.50 per share until June 30, 2022.
Units; each unit consists of 2 common shares and 1 common share purchase warrant
Source: Form D, filed Jun 5, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Harold David Gunn | Director, Executive |
| Michael Leschuk | Director |
| Julia Levy | Director |
| Jim Pankovich | Executive |
| Robert E. Pelzer | Director |
| Alun Rees | Executive |
| Simon Sutcliffe | Director, Executive |
| Gillian Vandermeirsch | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
305 4475 Wayburne Drive
Burnaby, A1, V5G 4X4
Burnaby, A1, V5G 4X4